| Authors: |
Kong BL; Oregon Health & Science University, Knight Cancer Institute, Portland, Oregon, USA. kongb.rx@gmail.com., Esquivel B; Ixlayer - VP Clinical Innovation - USA, New York, NY, USA.; GenXys - Chief Executive Officer, Vancouver, BC, Canada.; Global Genomic Medicine Consortium - Co Chair - USA/Global, Washington, DC, USA.; NIH/NCBI - Genetic Summaries Senior Editor - USA, Bethesda, Maryland, USA., Nagy M; Department of Pharmaceutical Services, Children's Cancer Hospital Egypt (57357), Cairo, Egypt.; Personalized Medication Management Unit, Children's Cancer Hospital Egypt (57357), Cairo, Egypt., Patrinos GP; University of Patras, School of Health Sciences, Department of Pharmacy, Division of Pharmacology and Biosciences, Laboratory of Pharmacogenomics and Individualised Therapy, Patras, Greece.; United Arab Emirates University, College of Medicine and Health Sciences, Department of Genetics and Genomics, Al-Ain, Abu Dhabi, United Arab Emirates.; Erasmus University Medical Centre, Faculty of Medicine and Health Sciences, Department of Pathology, Clinical Bioinformatics Unit, Rotterdam, Netherlands.; Hellenic Pasteur Institute, Laboratory of Innovative Therapeutics and Personalized Medicine, Athens, Greece., Jones JS; Department of Pharmaceutical Sciences, Texas Tech University Health Sciences Center Jerry H. Hodge School of Pharmacy, Dallas, Texas, USA., Rogers SL; American Society of Pharmacovigilance, Houston, Texas, USA.; Department of Translational Medical Sciences, College of Medicine, Texas A&M University, Bryan, Texas, USA.; Center for Genomic and Precision Medicine, Institute of Biosciences and Technology, Texas A&M University, Houston, Texas, USA.; School of Engineering Medicine, College of Medicine, Texas A&M University, Houston, Texas, USA. |
